{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chae YK"],"funding":["Bristol Myers Squibb Foundation (BMSF)","Center for Cancer Research (CCR)","NCI NIH HHS","Bristol Myers Squibb Foundation","Center for Cancer Research"],"pagination":["5593-5600"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11737520"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(24)"],"pubmed_abstract":["<h4>Purpose</h4>The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers is yet to be explored.<h4>Patients and methods</h4>Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumor is a prospective, multicenter (1,016 US sites), multicohort, single-arm phase II trial conducted through the Early Therapeutics and Rare Cancer SWOG/NCI Committee, assessing ipilimumab (anti-CTLA-4; 1 mg/kg every 6 weeks) and nivolumab (anti-PD-1; 240 mg every 2 weeks) in adults with advanced nonepithelial ovarian cancers who lack beneficial standard therapy. The primary outcome was overall response rate [ORR; complete response (CR)/partial response (PR)]; secondary outcomes"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer."],"pmcid":["PMC11737520"],"funding_grant_id":["U10CA180820","U10 CA180819","U10180821","UG1CA189872","UG1 CA189954","U10 CA180820","U10CA180819","UG1 CA189872","UG1CA233198","U10 CA180868","U10 CA180821","U10 CA180888","UG1CA189954","U10CA180868","UG1 CA233320","U10CA180888","UG1CA233320","UG1 CA233198"],"pubmed_authors":["McLeod CM","Adra N","Ryan CW","Ellerton JA","Lea J","Robinson WR","Wilkinson KJ","Lopez G","Chae YK","Blanke CD","Patel SP","Othus M","Walter A","Sharon E","Poklepovic A","Thomes Pepin J","Schallenkamp JM","Kim HS","Streicher H","Chung LI","Rampurwala MM","Kurzrock R","Whitman-Purves EM","Chen HX","Alden M","Appleman LJ"],"additional_accession":[]},"is_claimable":false,"name":"SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.","description":"<h4>Purpose</h4>The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers is yet to be explored.<h4>Patients and methods</h4>Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumor is a prospective, multicenter (1,016 US sites), multicohort, single-arm phase II trial conducted through the Early Therapeutics and Rare Cancer SWOG/NCI Committee, assessing ipilimumab (anti-CTLA-4; 1 mg/kg every 6 weeks) and nivolumab (anti-PD-1; 240 mg every 2 weeks) in adults with advanced nonepithelial ovarian cancers who lack beneficial standard therapy. The primary outcome was overall response rate [ORR; complete response (CR)/partial response (PR)]; secondary outcomes","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-01T06:26:48.286Z","creation":"2026-04-08T09:53:02.351Z"},"accession":"S-EPMC11737520","cross_references":{"pubmed":["39417692"],"doi":["10.1158/1078-0432.CCR-24-0606","10.1158/1078-0432.ccr-24-0606"]}}